Clinical Trial Update: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BYM338 for efficacy, safety, and tolerability in Sporadic Inclusion Body Myositis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sporadic Inclusion Body Myositis

Drugs mentioned

• BYM338

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Sporadic Inclusion Body Myositis | Phase 2 | Status: COMPLETED